Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

It's worth noting that between 1B and 1.5B in Mavyret sales the royalty goes up to 6%, so any increment is looking like it will fall in this royalty tier (12% vs 10% on the glecaprevir component when sales attributed to the PI are in the 500M and 750M range)
If somehow Mavyret sales get north of 1.5 B annually - a longer shot of course - the you are in the 14% royalty bracket (7% for the PI component)